New Hope for EU Lung Cancer Patients as Taletrectinib Enters EMA Review

TOKYO and NEW YORK – March 26, 2026 – Thousands of European patients with a rare and aggressive form of lung cancer may soon have a new treatment option, as pharmaceutical partners Eisai and Nuvation Bio announced that the European Medicines Agency (EMA) has validated their application for taletrectinib. The validation marks the official start of the review process for the highly selective, next-generation oral therapy aimed at adults with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

This milestone initiates a standard review timeline for full marketing authorisation in the European Union, following the drug's successful approvals in the United States, China, and Japan. The move signals a major step in the global expansion of taletrectinib and represents a significant moment for a patient population facing considerable unmet medical needs.

A New Contender for a Difficult-to-Treat Cancer

Non-small cell lung cancer is the most common type of lung cancer, and while ROS1 gene fusions are found in only about 2% of NSCLC cases, this subtype is particularly aggressive. A significant challenge in treating ROS1+ NSCLC is its propensity to spread to the brain. Approximately 35% of patients have brain metastases at their initial diagnosis, and the brain is the most common site of disease progression for those who have undergone prior treatments.

Current European guidelines from bodies like the European Society for Medical Oncology (ESMO) recommend first-generation tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib. While these drugs have been beneficial, their effectiveness can be limited by the development of drug resistance, particularly the G2032R mutation, and by side effects, including neurological issues. Furthermore, effectively treating tumors in the brain remains a critical hurdle.

Taletrectinib, marketed as IBTROZI® in the U.S. and Japan, was specifically designed to overcome these limitations. As a potent, CNS-active inhibitor, it can cross the blood-brain barrier to target tumors in the brain. Its molecular structure also allows it to effectively inhibit the cancer-driving ROS1 protein, even in the presence of common resistance mutations.

"The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC," said Terushige Iike, Chief Business Officer of Eisai Co., Ltd., in a statement. "With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe."

Backed by Robust Clinical Evidence

The application to the EMA is supported by a wealth of data from two pivotal Phase 2 studies, TRUST-I (conducted in China) and TRUST-II (conducted globally). A pooled analysis of these trials, published in the Journal of Clinical Oncology in April 2025, highlights the drug's profound and durable impact.

Key findings from the combined data demonstrate impressive efficacy:
* For treatment-naïve patients: The confirmed objective response rate (cORR) was 88.8%. More strikingly, the median duration of response (DoR) was 44.2 months, and the median progression-free survival (PFS) reached an unprecedented 45.6 months, suggesting long-term disease control.
* For patients previously treated with a TKI: The cORR was 55.8%, with a median DoR of 16.6 months and a median PFS of 9.7 months, offering a crucial option after initial therapies fail.
* For patients with brain metastases: Taletrectinib showed potent intracranial activity. In the TRUST-I study, the intracranial ORR was 88% for treatment-naïve patients and 75% for those previously treated.
* Overcoming Resistance: The therapy demonstrated a 67% ORR in patients whose cancer had developed the challenging G2032R resistance mutation, a common reason for treatment failure with older inhibitors.

Beyond its efficacy, taletrectinib has shown a manageable and favorable safety profile. Notably, the incidence of neurological side effects like dizziness and taste disturbances (dysgeusia) was low and predominantly mild, a significant advantage that could improve patients' quality of life compared to other available TKIs.

A Strategic Partnership for Global Reach

The European filing is the first major regulatory step under a strategic partnership forged between Eisai and Nuvation Bio in January 2026. Under the agreement, Nuvation Bio received an upfront payment of €50 million and is eligible for up to €145 million in further regulatory and commercial milestones, including a €25 million payment upon EU approval. Nuvation Bio will also receive tiered double-digit royalties on net sales in the licensed territories.

This collaboration allows Nuvation Bio, a focused oncology company, to leverage Eisai's vast global commercial infrastructure and expertise in Europe and other key markets, including Canada, Australia, and parts of the Middle East and Asia. For Eisai, a global pharmaceutical leader, taletrectinib strengthens its oncology portfolio with what it considers a potential "flagship oncology product in NSCLC."

Nuvation Bio retains full commercial rights in the U.S., where IBTROZI generated $24.7 million in revenue since its launch in June 2025. This hybrid commercialization model allows both companies to maximize the drug's global potential.

"Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe," stated David Hung, M.D., Founder, President, and CEO of Nuvation Bio. "This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it."

Navigating the Path to European Patients

The EMA's validation confirms the application is complete and ready for scientific evaluation. The fact that the agency accepted the filing for full approval consideration, rather than a more limited conditional approval, speaks to the comprehensive and compelling nature of the clinical data submitted by the companies.

While a positive opinion from the EMA would be a monumental victory, the journey to patient access across Europe is complex. Following EMA approval, each EU member state undertakes its own health technology assessment and reimbursement negotiations, a process that can cause significant delays, sometimes lasting months or even years in certain countries. Eisai and Nuvation Bio are also planning additional filings in the U.K., Canada, and other regions.

For now, the initiation of the EMA review provides a tangible beacon of hope. It moves a promising, targeted therapy one step closer to the European patients and clinicians who have been eagerly awaiting more effective and durable options to fight this challenging form of lung cancer.